Novel Benzimidazole- Platinum(II) Complexes: Synthesis, Characterization, Antimicrobial and Anticancer Activity

Synthesis of novel pyrimidine-based Schiff base complexes: Targeting Amyloid-β aggregation in Alzheimer's disease

A novel Schiff base with imine/amine donors, 5-((3,3-diphenylalilidene)amino)pyrimidine-4-amine (L), and its new Platinum(II) and Ruthenium(II) complexes (I and II) were synthesized and characterized using FT-IR, 1H NMR, 13C NMR, mass spectrometry and elemental analyses. The ability of these complexes to inhibit amyloid beta (Aβ1-42) aggregation was evaluated using the human neuroblastoma cell line (SH-SY5Y). The complexes effectively inhibited Aβ1-42 aggregation at a 1:1 M ratio. Both complexes increased cell viability up to 80 % at concentrations of 10 μM. At this concentration, the cell viability value found by Aβ1-42 aggregation is around 65 %. Aggregation kinetics were fluorometrically monitored using Thioflavin T. These findings were further supported by scanning electron microscopy and transmission electron microscopy. In addition, the interaction of the complexes with Aβ1-16 was investigated using MALDI-TOF/MS and 1H NMR spectroscopy. All findings showed that Aβ1-42 in both complexes is active in the inhibition of amyloid aggregation.

Selective Oxidative Methyl C-H Functionalization of Butylated Hydroxytoluene toward Arylimines/N-Heterocycles

A metal-free and selective oxidative methyl C-H functionalization of BHT with aniline compounds has been developed. This innovative method enables the facile and efficient synthesis of a diverse array of BHT-functionalized N-containing skeletons, including arylamines, benzoxazoles, benzothiazoles, benzimidazoles, quinazolines, and quinazolinones, all of which are challenging to access. The control experiment involving TEMP18O suggests that the radical adduct of TEMPO with the benzyl radical of BHT may serve as an intermediate.

Platinum and Palladium Complexes as Promising Sources for Antitumor Treatments

There is a need for new, safer, and more effective agents to treat cancer. Cytostatics that have transition metals at their core have attracted renewed interest from scientists. Researchers are attempting to use chemotherapeutics, such as cisplatin, in combination therapy (i.e., in order to enhance their effectiveness). Moreover, studies are being carried out to modify molecules, by developing them into multinuclear structures, linking different compounds to commonly used drugs, or encapsulating them in nanoparticles to improve pharmacokinetic parameters, and increase the selectivity of these drugs. Therefore, we attempted to organize recent drug findings that contain palladium and platinum atoms in their structures.